Market Research Logo

Malignant Pleural Mesothelioma - Pipeline Review, H2 2016

Malignant Pleural Mesothelioma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Mesothelioma – Pipeline Review, H2 2016, provides an overview of the Malignant Pleural Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Mesothelioma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Pleural Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 25, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 2 molecules, respectively.Malignant Pleural Mesothelioma.

Malignant Pleural Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Pleural Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Pleural Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Mesothelioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Malignant Pleural Mesothelioma Overview
Therapeutics Development
Pipeline Products for Malignant Pleural Mesothelioma - Overview
Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis
Malignant Pleural Mesothelioma - Therapeutics under Development by Companies
Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes
Malignant Pleural Mesothelioma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Malignant Pleural Mesothelioma - Products under Development by Companies
Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes
Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development
Advantagene, Inc.
Amphera BV
AnGes MG, Inc.
ArQule, Inc.
Bayer AG
Biogen Inc
Bionomics Limited
Biotecnol Limited
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CanBas Co., Ltd.
Concordia International Corp
Eli Lilly and Company
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd.
Genelux Corporation
GlaxoSmithKline Plc
Juno Therapeutics Inc.
MedImmune LLC
Merck & Co., Inc.
Millennium Pharmaceuticals Inc
MolMed S.p.A.
Morphotek, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Oxford BioMedica Plc
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Sellas Inc
Targovax ASA
VasGene Therapeutics, Inc.
Verastem, Inc.
Virttu Biologics Limited
Vyriad Inc
Malignant Pleural Mesothelioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alisertib - Drug Profile
amatuximab - Drug Profile
anetumab ravtansine - Drug Profile
bevacizumab - Drug Profile
BG-00001 - Drug Profile
BMS-986148 - Drug Profile
BNC-105 - Drug Profile
CBP-501 - Drug Profile
Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile
Cellular Immunotherapy to Target Mesothelin for Oncology - Drug Profile
Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile
CSG-MESO - Drug Profile
defactinib hydrochloride - Drug Profile
durvalumab - Drug Profile
durvalumab + tremelimumab - Drug Profile
galinpepimut-S - Drug Profile
ganetespib - Drug Profile
GEN-0101 - Drug Profile
Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile
GLONC-1 - Drug Profile
GSK-2256098 - Drug Profile
HSV-1716 - Drug Profile
iCasp9M28z - Drug Profile
JTCR-016 - Drug Profile
LY-3023414 - Drug Profile
MesoCancerVac - Drug Profile
MesoCART - Drug Profile
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
MTG-201 - Drug Profile
napabucasin - Drug Profile
NGR-hTNF - Drug Profile
nintedanib - Drug Profile
nivolumab - Drug Profile
Oncolytic Virus for Malignant Pleural Mesothelioma - Drug Profile
Oncolytic Virus to Target CD46 for Malignant Pleural Mesothelioma - Drug Profile
ONCOS-102 - Drug Profile
OXB-301 - Drug Profile
pegargiminase - Drug Profile
pembrolizumab - Drug Profile
porfimer sodium - Drug Profile
rAd-IFN - Drug Profile
S-588210 - Drug Profile
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile
TargomiRs - Drug Profile
TB-535 - Drug Profile
tivantinib - Drug Profile
trabectedin - Drug Profile
Vas-01 - Drug Profile
VS-5584 - Drug Profile
Malignant Pleural Mesothelioma - Dormant Projects
Malignant Pleural Mesothelioma - Discontinued Products
Malignant Pleural Mesothelioma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Malignant Pleural Mesothelioma, H2 2016
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H2 2016
Malignant Pleural Mesothelioma - Pipeline by AnGes MG, Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by ArQule, Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Biogen Inc, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Biotecnol Limited, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Concordia International Corp, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Eli Lilly and Company, H2 2016
Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2016
Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H2 2016
Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by MedImmune LLC, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Sellas Inc, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Targovax ASA, H2 2016
Malignant Pleural Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H2 2016
Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H2 2016
Malignant Pleural Mesothelioma - Pipeline by Vyriad Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Malignant Pleural Mesothelioma - Dormant Projects, H2 2016
Malignant Pleural Mesothelioma - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Malignant Pleural Mesothelioma, H2 2016
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report